Pragmatic, Randomized Optimal Platelet and Plasma Ratios

PHASE3CompletedINTERVENTIONAL
Enrollment

680

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Trauma
Interventions
BIOLOGICAL

1:1:1 Blood Transfusion Ratio

Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.

BIOLOGICAL

1:1:2 Blood Transfusion Ratio

Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.

Trial Locations (12)

21201

University of Maryland School of Medicine, Baltimore

35233

University of Alabama, Birmingham

38103

University of Tennessee Health Science Center, Memphis

45221

University of Cincinnati, Cincinnati

53226

Medical College of Wisconsin, Milwaukee

77030

University of Texas Health Science Center- Memorial Hermann Hospital, Houston

85721

University of Arizona, Tucson

90033

University of Southern California, Los Angeles, Los Angeles

94143

University of California, San Francisco, San Francisco

97239

Oregon Health and Science University, Portland

98104

University of Washington- Harborview Medical Center, Seattle

M4N 3M5

Sunnybrook Health Science Center, Toronto

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Resuscitation Outcomes Consortium

NETWORK

collaborator

Defence Research and Development Canada

INDUSTRY

lead

The University of Texas Health Science Center, Houston

OTHER

NCT01545232 - Pragmatic, Randomized Optimal Platelet and Plasma Ratios | Biotech Hunter | Biotech Hunter